In the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled Latitude PsO 3001 and 3002 studies, more than half of patients treated with zasocitinib achieved clear ...
Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies Nearly 60% of adolescents ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults furt ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis ...
UCB, a global biopharmaceutical company, today announced new data in moderate-to-severe plaque psoriasis (PSO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, March 27–31.
Transjakarta marks 12 years with Rp 73.8T economic impact, serving 1.4 million daily passengers across 92.5% of Jakarta.
One of the key masterminds behind the audacious $22.5-million gold heist at Toronto’s Pearson airport three years ago had ...
Buying continued at the Pakistan Stock Exchange (PSX), with the benchmark KSE-100 Index gaining nearly 4,200 points during ...
Pearson’s first global brand campaign in five years is designed to illustrate all of its products and services, from K–12 and ...
Zacks Investment Research on MSN
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why
Shares of Protagonist Therapeutics PTGX have gained nearly 7% over the past week. The upside came after the company announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results